Les meilleurs doctors en Israël pour votre Thérapie CAR T - TOP 14 des médecins

Le Dr Ron Ram a réalisé plusieurs centaines de greffes de cellules souches et a publié plus de 30 articles scientifiques en hématologie et en oncologie.

• Certifié par le Conseil (Board-certified) en médecine interne, hématologie et oncologie médicale
• Formation de spécialisation (Fellowship) effectuée au New York Medical College
• Spécialisé dans les hémopathies malignes et les transplantations
• Contributeur académique, auteur de chapitres de manuels de médecine

Le Dr Ram Ron est spécialisé en thérapie par cellules CAR T au Sourasky Medical Center (Ichilov), apportant une vaste expertise à ce traitement de pointe.

• Axé sur les thérapies cellulaires de pointe
• Exerce dans un centre médical de premier plan en oncologie
• Dédié aux approches de traitement personnalisées

Cheffe du service d'Oncohématologie Pédiatrique à l'Hôpital pour Enfants Dana Dwek – Le Dr Ronit El Hasid est spécialisée dans les greffes de moelle osseuse et de sang chez les enfants.

• A réalisé plus de 300 procédures de transplantation
• A publié plus de 50 articles médicaux
• A présenté des recherches lors de plus de 40 conférences
• Membre (Fellow) de l'Association Américaine d'Hématologie
• Formation effectuée au City of Hope Hospital à Los Angeles

Le Dr Michael Shapira est spécialisé en greffe de moelle osseuse au Centre médical Sourasky (Ichilov), avec une vaste expérience dans ce domaine.

• Diplômé de la faculté de médecine de l'Université hébraïque en 1999
• Spécialisé en médecine interne au Centre médical Hadassah
• Médecin senior en greffe de moelle osseuse à Hadassah
• Parle couramment l'anglais et l'hébreu

Directeur de l'hémato-oncologie pédiatrique au Centre médical Sourasky – spécialisé dans la thérapie par cellules CAR-T pour les enfants atteints de troubles sanguins et de sarcomes.

• Pédiatre senior à l'Hôpital pour enfants Dana
• Formation à l'Institut orthopédique Rizzoli – l'un des centres mondiaux de référence pour le cancer des os
• Membre de l'ISPHO – l'association israélienne d'hémato-oncologie pédiatrique
• Coordonne les programmes de traitement des sarcomes pour enfants

Fort de 31 ans d'expérience, le Dr Aviv est spécialisé dans la thérapie par cellules CAR T au Centre médical Sourasky (Clinique Ichilov).

• Se concentre exclusivement sur l'oncohématologie
• Vaste expérience des thérapies cellulaires avancées
• Exerce dans l'un des principaux centres médicaux d'Israël

Le Dr Yair a apporté des contributions significatives à l'hématologie, en particulier dans le domaine de la leucémie lymphoïde chronique, et est détenteur de nombreuses récompenses et de publications scientifiques.

• Lauréat de plusieurs prix prestigieux, dont le Klitzberg Oncology Award
• Membre des associations d'hématologie israélienne et américaine
• Formation approfondie en hématologie au Centre médical de Tel Aviv
• Actif dans la recherche, avec des subventions de la Fondation scientifique israélienne (Israeli Science Foundation)

Dr. Iris Kventsel, MD, is a pediatric hemato-oncologist and bone marrow transplant (BMT) specialist at Sheba Medical Center. She is an attending physician in the Pediatric Hemato-Oncology and BMT Division at the Edmond and Lily Safra Children’s Hospital. Her clinical focus is pediatric sarcomas, including Ewing sarcoma, osteosarcoma, and rhabdomyosarcoma.

She provides multidisciplinary care, including transplant and cellular therapies. She also uses current chemotherapy protocols and targeted therapies for complex childhood cancers.

Her research focuses on genetic cancer predisposition, including Li-Fraumeni syndrome, and cancer susceptibility genes. She has published in pediatric oncology, stem cell biology, and surgical oncology (HIPEC). She is on the academic staff at Tel Aviv University. Education: MD, Technion; Pediatrics residency, Assaf HaRofeh; Pediatric Hemato-Oncology fellowship, Sheba.

Dr. Hana Golan, MD, heads the Pediatric Hemato-Oncology and Bone Marrow Transplantation (BMT) Division at Sheba Medical Center. She specializes in childhood cancers, with a focus on neuroblastoma and other high-risk solid tumors.

She leads one of the region’s most advanced pediatric oncology programs. She manages complex, high-risk cases and practices at a hospital ranked in the global top 10.

She is the principal investigator of the High-Risk Neuroblastoma ESIOP protocol. She serves as an investigator in international Phase I/II trials and as the national coordinator of multicenter oncology protocols. She led the development of computerized chemotherapy protocols and patient databases to improve safety.

She earned her MD from the Technion. She completed residencies in pediatrics and pediatric hemato-oncology at Sheba. She conducted advanced research in transplantation immunology at the Weizmann Institute. She is board-certified in Pediatrics and Pediatric Hematology-Oncology. She is a Senior Lecturer at the Sackler Faculty of Medicine, Tel Aviv University. Her research focuses on cancer stem cells, targeted therapies, treatment-resistant malignancies, and cannabinoid-related oncology.

Dr. Hila Magen, MD, leads the Multiple Myeloma and Amyloidosis Unit at Sheba Medical Center. She is a hemato-oncologist with over 35 years of experience. She is a leading Israeli expert in multiple myeloma and plasma cell disorders.

She runs a program that provides personalized care and early access to clinical trials. This includes CAR-T therapy for high-risk and relapsed or refractory myeloma and amyloidosis. Dr. Magen is a principal investigator in point-of-care CAR-T studies. She brings new immunotherapies into routine care.

Training: Fellowships in Multiple Myeloma (UAMS) and Lymphocytic Leukemia (MD Anderson). Academic: Instructor, Tel Aviv University. Research: Author of 100+ publications, contributor to landmark myeloma studies, and reviewer for international journals.

Prof. Avichai Shimoni, MD, is Director of Bone Marrow Transplantation at Sheba Medical Center. He is a hemato-oncologist with over 30 years of experience in bone marrow transplantation, cellular therapies, and advanced blood cancer care.

He leads a high-volume program for complex, high-risk blood cancers. He performs allogeneic and autologous transplants. He also provides CAR T-cell therapy for leukemia, lymphoma, and multiple myeloma. He completed a bone marrow transplantation fellowship at MD Anderson Cancer Center.

He is Chairman of Hematology at Tel Aviv University and a Professor of Hematology. He has authored more than 250 scientific papers. His research focuses on CAR T-cell therapy and stem cell transplantation. He is often listed among Israel's Best Doctors (Forbes 2025 and 2026).

Dr. Abraham Avigdor, MD, is Director of the Institute of Hematology and Co‑Director of the Hematology & Bone Marrow Transplantation Division at Sheba Medical Center. He is an international leader in lymphoma, CAR‑T, and advanced hemato‑oncology with more than 35 years of experience. His clinical focus includes lymphomas, multiple myeloma, and complex blood cancers.

He is a pioneer in CAR‑T integration. He leads cellular therapy and bone marrow transplantation programs (autologous and allogeneic). He also advances stem cell therapies and precision diagnostics, including PET/CT‑based prognostics. His work includes immunotherapy and targeted regimens and the development of innovative, data‑driven protocols.

He collaborates with LYSA, EMCL, and international PET groups. He has authored more than 130 publications. Key roles include Founder and President of the Israeli Lymphoma Working Group, former Chair of the Israeli Lymphoma Study Group, and Senior Lecturer at Tel Aviv University. Education: MD, Ben‑Gurion University; residency, Sheba Medical Center; postdoctoral fellowship, Weizmann Institute. Awards include the Knesset Prize, the Israeli Ministry of Health Award, and the Sackler Prize.

Prof. Elad Jacoby, MD

Global Leader in Pediatric Hemato-Oncology, CAR-T Therapy & Bone Marrow Transplantation

About Prof. Elad Jacoby

Prof. Elad Jacoby is one of the world’s leading experts in pediatric hemato-oncology and advanced cellular therapies, serving as the Head of the Pediatric Cell Therapy Center and Medical Director of the Advanced Biotherapy Center at Sheba Medical Center. With nearly two decades of clinical and research experience, he is widely recognized for transforming the treatment landscape for children with complex and treatment-resistant blood cancers.

Prof. Jacoby is a pioneer of CAR-T cell therapy in Israel, having led the implementation of one of the first national programs for pediatric leukemia. His work focuses on delivering highly personalized, cutting-edge therapies to children who often have limited or no remaining standard treatment options.

Beyond his clinical leadership, he is an Associate Professor at Tel Aviv University, actively involved in training the next generation of physicians while leading groundbreaking international research in immunotherapy and cellular medicine.

Clinical Expertise & Special Focus

Prof. Jacoby specializes in the most advanced and life-saving treatments for children and young patients with hematologic malignancies, including:

• CAR-T Cell Therapy (Chimeric Antigen Receptor T-Cells)
  Personalized immunotherapy designed to reprogram the patient’s immune system to fight cancer
• Bone Marrow & Stem Cell Transplantation (BMT)
  Including complex and high-risk transplant cases
• Pediatric Leukemia & Lymphoma
  Acute lymphoblastic leukemia (ALL), relapsed/refractory leukemias, and aggressive lymphomas
• Advanced Cellular Immunotherapy
  Including anti-viral T-cell therapies for immunocompromised patients
• Mitochondrial Augmentation Therapy (MAT)
  First-in-human innovative treatments for rare and complex conditions

His approach combines precision medicine, immunotherapy, and transplantation, allowing for comprehensive, individualized care even in the most challenging cases.

Innovation & Research Leadership

Prof. Jacoby is at the forefront of global innovation in pediatric cancer care. He leads and participates in international clinical trials focused on next-generation therapies, including:

• CAR-T therapies for resistant leukemias and lymphomas
• Novel cellular therapies targeting cancer and severe infections
• Breakthrough research in mitochondrial medicine and immune system modulation

He has authored over 240 scientific publications in leading medical journals and collaborates with top institutions worldwide, including:

• Johns Hopkins Hospital (USA)
• National Cancer Institute (NCI), USA
• International pediatric oncology and CAR-T research networks

His research directly translates into real-world treatment options, giving patients access to therapies not widely available elsewhere.

Patient-Centered Approach

Prof. Jacoby is known not only for his clinical excellence but also for his deep commitment to patient-centered care. Every child and family receives:

• A fully personalized treatment plan tailored to the disease and patient profile
• Access to the most advanced therapies available globally
• Close monitoring by a multidisciplinary team of experts
• Compassionate guidance throughout every stage of treatment

His philosophy is simple: combine innovation with empathy, ensuring that families feel supported, informed, and confident in their care journey.

Leadership & Roles

• Head, Pediatric Cell Therapy Center, Sheba Medical Center
• Medical Director, Advanced Biotherapy Center, Sheba Medical Center
• Senior Lecturer / Associate Professor, Tel Aviv University School of Medicine
• Member, CAR-T Cell Taskforce (IBFM Study Group)
• Member, Institutional Review Board, Sheba Medical Center

Education & International Training

• MD, Tel Aviv University School of Medicine
• Pediatrics Residency, Sheba Medical Center
• Fellowship in Pediatric Hematology & Oncology, Johns Hopkins Hospital, USA
• Clinical & Research Fellowship, National Cancer Institute (NCI), USA

Board Certifications

• Pediatrics
• Pediatric Hematology & Oncology

Why Patients Choose Prof. Elad Jacoby

• Pioneer of pediatric CAR-T therapy in Israel
• Leader in integrating CAR-T with bone marrow transplantation
• Access to exclusive clinical trials and next-generation treatments
• Extensive experience in complex and relapsed cases
• Internationally recognized expert with a strong academic and research background
• Dedicated to delivering hope through innovation and personalized care

A Leader in the Future of Pediatric Cancer Care

Through his work, Prof. Jacoby continues to redefine what is possible in treating childhood cancers—bringing together science, innovation, and compassionate care to improve outcomes and give new hope to patients and their families worldwide.